# Table of Contents

## INTRODUCTION

About the Montana Tuberculosis Program Manual ...........1.2

Purpose ......................................................... 1.2

Audience ........................................................... 1.2

How to Use This Manual .......................... 1.3

Portable document format................................. 1.3

Hyperlinks ......................................................... 1.3

Cross-references ................................................ 1.3

Forms ................................................................. 1.3

Bookmarks and display size ............................... 1.4

Printing ............................................................... 1.5

Icons ................................................................. 1.6

Abbreviations ..................................................... 1.7

Purpose of Tuberculosis Control ................. 1.10

Montana Laws and Rules on Tuberculosis Control ........... 1.11

Montana and National Objectives .................. 1.12

Montana Tuberculosis Program objectives—2009 .................. 1.12

National program objectives .............................. 1.13

Standards .......................................................... 1.15

Montana evaluation plan 2006–2007 ......................... 1.16

Roles, Responsibilities, and Contact Information .......... 1.17

Montana Tuberculosis Program staff ...................... 1.17

Local public health agencies and private medical providers .... 1.18

State laboratory .................................................. 1.19

Resources and References ............................... 1.20

## SURVEILLANCE

Introduction ..................................................... 2.2

Purpose ........................................................... 2.2

Policy .............................................................. 2.5

Laws and rules ................................................. 2.5

Reporting Tuberculosis ......................... 2.6

Reporting suspected or confirmed cases of tuberculosis to the local public health agency .................. 2.8

Required reports from local public health agencies to the Montana Tuberculosis Program ......................... 2.10

Data Collection Forms .......................... 2.11

Genotyping ...................................................... 2.12

References ....................................................... 2.14

## TARGETED TESTING FOR LATENT TUBERCULOSIS INFECTION

Introduction ..................................................... 3.2

Purpose ........................................................... 3.2

Policy .............................................................. 3.2

High-Risk Groups ......................................... 3.3

When to Conduct Targeted Testing ............... 3.5

Approaches to increasing targeted testing and treatment for latent tuberculosis infection ........... 3.5

Screening for latent tuberculosis infection in facilities .......... 3.6

References ....................................................... 3.7
## Diagnosis of Latent Tuberculosis Infection

**Quick Start Check List** ........................................... 7.2

**Introduction** .................................................. 7.4
- **Purpose** ..................................................... 7.4
- **Policy** ....................................................... 7.4
- **Forms** ....................................................... 7.4

**Tuberculosis Classification System** .... 7.5

**High-Risk Groups** ............................................. 7.6

**Diagnosis of Latent Tuberculosis Infection** ................................................... 7.8
- Mantoux tuberculin skin testing .............................. 7.8
- Candidates for Mantoux tuberculin skin testing ........ 7.9
- Administration of the tuberculin skin test .............. 7.12
- Measurement of the tuberculin skin test .................. 7.14
- Interpretation of the tuberculin skin test ................ 7.15
- Human immunodeficiency virus screening ............... 7.17
- Follow-up activities ........................................ 7.17
- Chest radiography ........................................... 7.17

**Resources and References** ............................... 7.20

## Treatment of Latent Tuberculosis Infection

**Quick Start Check List** ........................................... 8.2

**Introduction** .................................................. 8.4
- **Purpose** ..................................................... 8.4
- **Forms** ....................................................... 8.5

**Whom to Treat** ................................................. 8.6
- Susceptible and vulnerable contacts ...................... 8.7
- Tuberculin skin test results of 5 mm or more ......... 8.8
- Tuberculin skin test results of 10 mm or more ........ 8.8
- Tuberculin skin test results of 15 mm or more ....... 8.9

**Treatment Regimens and Dosages** .... 8.10
- Regimens ...................................................... 8.11
- **Dosages** ................................................... 8.12
- **Side Effects and Adverse Reactions** ................. 8.13
- Basic monitoring steps ..................................... 8.13
- Reporting reactions ......................................... 8.15
- Monitoring for side effects and adverse reactions by antituberculosis drug ........ 8.16

**Adherence** ....................................................... 8.19
- Monthly assessment of adherence ......................... 8.19
- Directly observed therapy ................................ 8.20

**Completion of Therapy** ..................................... 8.21

**Treatment in Special Situations** ................. 8.23
- Human immunodeficiency virus and latent tuberculosis infection ........ 8.23
- Alcoholism ....................................................... 8.24
- Pregnancy and breastfeeding ............................... 8.25

**Resources and References** ............................... 8.26

## Case Management

**Quick Start Check List** ........................................... 9.2

**Introduction** .................................................. 9.8
- **Purpose** ..................................................... 9.8
- **Policy** ....................................................... 9.9
- **Forms** ....................................................... 9.9
- **Acknowledgments** ....................................... 9.9

**Initial Assessment** ........................................... 9.11
- Cultural sensitivity and language issues .......... 9.11
- Patient’s medical records .............................. 9.12
- Assessment site ........................................... 9.12
- Discharge planning ....................................... 9.12
- Initial assessment activities ......................... 9.12

**Treatment Plan** ............................................... 9.17
- Treatment plan components ............................. 9.18
- Planning activities ......................................... 9.19
- Implementation activities ................................ 9.19
# Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing Assessment and Monitoring</td>
<td>9.22</td>
</tr>
<tr>
<td>Ongoing assessment activities</td>
<td>9.22</td>
</tr>
<tr>
<td>Monitoring side effects and adverse reactions</td>
<td>9.26</td>
</tr>
<tr>
<td>Monitoring bacteriologic improvement</td>
<td>9.27</td>
</tr>
<tr>
<td>Completion of Therapy</td>
<td>9.30</td>
</tr>
<tr>
<td>Verifying adequate course of treatment</td>
<td>9.30</td>
</tr>
<tr>
<td>Calculating completion of therapy</td>
<td>9.30</td>
</tr>
<tr>
<td>Evaluation</td>
<td>9.32</td>
</tr>
<tr>
<td>Directly Observed Therapy</td>
<td>9.33</td>
</tr>
<tr>
<td>Candidates for directly observed therapy</td>
<td>9.33</td>
</tr>
<tr>
<td>How to deliver directly observed therapy</td>
<td>9.34</td>
</tr>
<tr>
<td>Adherence to directly observed therapy</td>
<td>9.35</td>
</tr>
<tr>
<td>Incentives and Enablers</td>
<td>9.38</td>
</tr>
<tr>
<td>Legal Orders</td>
<td>9.39</td>
</tr>
<tr>
<td>Resources and References</td>
<td>9.41</td>
</tr>
<tr>
<td>Contact Investigation</td>
<td>10.2</td>
</tr>
<tr>
<td>Quick Start Check List</td>
<td>10.2</td>
</tr>
<tr>
<td>Introduction</td>
<td>10.6</td>
</tr>
<tr>
<td>Purpose</td>
<td>10.6</td>
</tr>
<tr>
<td>Policy</td>
<td>10.7</td>
</tr>
<tr>
<td>Forms</td>
<td>10.8</td>
</tr>
<tr>
<td>Structure of a Contact Investigation</td>
<td>10.9</td>
</tr>
<tr>
<td>Basic steps of a contact investigation</td>
<td>10.9</td>
</tr>
<tr>
<td>Contact investigation plan</td>
<td>10.9</td>
</tr>
<tr>
<td>Decision to Initiate a Contact Investigation</td>
<td>10.10</td>
</tr>
<tr>
<td>Factors predicting transmission of tuberculosis</td>
<td>10.10</td>
</tr>
<tr>
<td>Deciding to initiate a contact investigation</td>
<td>10.13</td>
</tr>
<tr>
<td>Time Frames for Contact Investigation</td>
<td>10.16</td>
</tr>
<tr>
<td>Information about the index patient and transmission sites</td>
<td>10.16</td>
</tr>
<tr>
<td>Contact evaluation and treatment</td>
<td>10.18</td>
</tr>
<tr>
<td>Ongoing management activities</td>
<td>10.19</td>
</tr>
<tr>
<td>Infectious Period</td>
<td>10.21</td>
</tr>
<tr>
<td>Index Patient Interviews</td>
<td>10.24</td>
</tr>
<tr>
<td>Preinterview preparation</td>
<td>10.24</td>
</tr>
<tr>
<td>General guidelines for interviewing an index patient</td>
<td>10.25</td>
</tr>
<tr>
<td>Field Investigation</td>
<td>10.26</td>
</tr>
<tr>
<td>Contact Priorities</td>
<td>10.28</td>
</tr>
<tr>
<td>Index patient with positive acid-fast bacilli sputum smear results or cavitary tuberculosis</td>
<td>10.29</td>
</tr>
<tr>
<td>Index patient with negative acid-fast bacilli sputum smear results</td>
<td>10.30</td>
</tr>
<tr>
<td>Index patient with negative bacteriologic results and abnormal chest radiographs not consistent with tuberculosis</td>
<td>10.31</td>
</tr>
<tr>
<td>Contact Evaluation, Treatment, and Follow-up</td>
<td>10.32</td>
</tr>
<tr>
<td>Immunocompromised contacts and children under 5</td>
<td>10.33</td>
</tr>
<tr>
<td>Immunocompetent adults and children 5 and older (high- and medium-priority contacts)</td>
<td>10.35</td>
</tr>
<tr>
<td>Contacts with prior positive tuberculin skin tests</td>
<td>10.37</td>
</tr>
<tr>
<td>When to Expand a Contact Investigation</td>
<td>10.38</td>
</tr>
<tr>
<td>Guidelines for expanding an investigation</td>
<td>10.38</td>
</tr>
<tr>
<td>Low-priority contacts</td>
<td>10.40</td>
</tr>
<tr>
<td>Data Management and Evaluation of Contact Investigations</td>
<td>10.41</td>
</tr>
<tr>
<td>Reasons contact investigation data are needed</td>
<td>10.41</td>
</tr>
<tr>
<td>Approach</td>
<td>10.42</td>
</tr>
<tr>
<td>Index patient and contact data</td>
<td>10.43</td>
</tr>
<tr>
<td>Evaluation of a contact investigation</td>
<td>10.45</td>
</tr>
</tbody>
</table>
Outbreak Investigation..........................10.47
Definition of a tuberculosis outbreak.............10.47
Deoxyribonucleic acid genotyping ..................10.48
Resources and References .........................10.49

LABORATORY SERVICES
Introduction...........................................11.2
Purpose..........................................................11.2
Policy.................................................................11.2
Laboratory Contact Information..............11.3
Available Laboratory Tests..................11.4
Specimen Collection ..............................11.7
How to perform spontaneous sputum
collection at a healthcare facility ...............11.9
How to direct a patient to perform
spontaneous sputum collection at home ..........11.10
Induced sputum collection at a
healthcare facility ........................................11.10
How to collect gastric aspirates .................11.11
Bronchoscopy or collection of
extrapulmonary specimens ............................11.11
Specimen Shipment .................................11.12
Resources and References .................11.14

PATIENT EDUCATION
Introduction..............................................12.2
Purpose............................................................12.2
Forms.................................................................12.2
General Guidelines .................................12.3
Education Topics ........................................12.4
Language and comprehension barriers.........12.4
Medical diagnosis...........................................12.5
Contact investigation ......................................12.5
Isolation............................................................12.6
Side effects and adverse reactions ...............12.6
Adherence.........................................................12.7
Patient Education Materials ......................12.8
Resources and References .......................12.9

CONFIDENTIALITY
Introduction............................................13.2
Purpose.........................................................13.2
Policy.............................................................13.2
Health Insurance Portability and
Accountability Act (HIPAA)......................13.3
Centers for Disease Control and Prevention
guidance on HIPAA ......................................13.3
Montana HIPAA policies ............................13.4
National Guidelines .................................13.5
Resources and References .......................13.6
TRANSFER NOTIFICATIONS
Introduction........................................... 14.2
Purpose.............................................................. 14.2
Policy ................................................................. 14.2
When to Initiate a Notification ............ 14.3
How to Issue a Notification............... 14.4
References .................................................... 14.6

SUPPLIES, MATERIALS, AND SERVICES
Introduction............................................. 15.2
Specimen Collection
and Shipment Supplies ....................... 15.3
Tuberculosis Medications
for Active and Suspect Cases ............ 15.4
Medications for Latent
Tuberculosis Infection ...................... 15.5
Incentives and Enablers .................... 15.6
Healthcare Staff
Training and Education ................... 15.7

GLOSSARY